PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
30254425-6	2018	Furthermore, both tacrolimus and anti-VEGF significantly decreased the VEGF-A expression on Days 7 and 14, with no significant difference between the two groups.	Tacrolimus	18-28	vascular endothelial growth factor A	Rattus norvegicus	71-77	
21138364-0	2011	The impact of tacrolimus on vascular endothelial growth factor in experimental corneal neovascularization.	Tacrolimus	14-24	vascular endothelial growth factor A	Rattus norvegicus	28-62	
21138364-1	2011	PURPOSE: To investigate the impact of tacrolimus on vascular endothelial growth factor (VEGF) in experimental corneal neovascularization (NV) immunohistochemically.	Tacrolimus	38-48	vascular endothelial growth factor A	Rattus norvegicus	52-86	
21138364-1	2011	PURPOSE: To investigate the impact of tacrolimus on vascular endothelial growth factor (VEGF) in experimental corneal neovascularization (NV) immunohistochemically.	Tacrolimus	38-48	vascular endothelial growth factor A	Rattus norvegicus	88-92	
21138364-11	2011	The mean intensity of the epithelial VEGF immunostaining of the intraperitoneally tacrolimus-treated group was less than that of its sham group (p = 0.002), while the mean intensity of the stromal VEGF staining of the topically tacrolimus-treated group was lesser than that of its sham group (p = 0.042).	Tacrolimus	82-92	vascular endothelial growth factor A	Rattus norvegicus	37-41	
21138364-11	2011	The mean intensity of the epithelial VEGF immunostaining of the intraperitoneally tacrolimus-treated group was less than that of its sham group (p = 0.002), while the mean intensity of the stromal VEGF staining of the topically tacrolimus-treated group was lesser than that of its sham group (p = 0.042).	Tacrolimus	82-92	vascular endothelial growth factor A	Rattus norvegicus	197-201	
21138364-12	2011	The intensities of the endothelial VEGF immunostaining of the intraperitoneally and topically tacrolimus-treated groups were less than those of the sham groups (p = 0.038, p = 0.032).	Tacrolimus	94-104	vascular endothelial growth factor A	Rattus norvegicus	35-39	
21138364-13	2011	CONCLUSION: Systemic and topical administration of tacrolimus may be beneficial in the prevention of corneal NV because of its effect on VEGF.	Tacrolimus	51-61	vascular endothelial growth factor A	Rattus norvegicus	137-141